ANGLE PLC S/ADR - ANPCY STOCK NEWS

ANGLE plc (OTCQX: ANPCY) announced the approval of 3,000,000 LTIP options and 4,942,500 staff share options under its existing plans. These options are designed to enhance shareholder value, tied to performance metrics over three years. As of now, the company holds options over 32,406,146 Ordinary Shares, approximately 12.1% of its share capital. The share options will have specific performance conditions and will vest based on the CAGR of share price. The expiration date for certain existing options has been extended to November 17, 2022.

ANGLE plc (OTCQX:ANPCY) has issued 70,000 new ordinary shares following the exercise of employee options. These shares, valued at £0.10 each, will rank pari passu with existing shares and are set to be admitted to AIM on November 18, 2021. This raises the total number of ordinary shares to 235,043,717. ANGLE specializes in liquid biopsy technologies, focusing on cancer diagnostics, and aims for FDA clearance for its Parsortix system, which has shown promising results in clinical trials for metastatic breast cancer and ovarian cancer.

ANGLE plc (OTCQX:ANPCY) will present at the Jefferies London Healthcare Conference on November 16 at 10:00 AM GMT. The conference is the largest healthcare-focused investor event in Europe and features CEO Andrew Newland and CFO Ian Griffiths. ANGLE's innovative Parsortix liquid biopsy technology enables comprehensive cancer analysis through non-invasive blood tests, with a CE Mark in Europe and a pending FDA submission for breast cancer applications. The company is advancing clinical studies to enhance ovarian cancer detection accuracy.

ANGLE plc (OTCQX:ANPCY) presented findings at the NCRI Festival indicating that longitudinal analysis of circulating tumor cells (CTCs) using the Parsortix system can effectively predict treatment response in metastatic prostate cancer patients undergoing docetaxel therapy. The study revealed that the KLK2 gene expression on CTCs was a more reliable biomarker for assessing cancer progression than current PSA levels. This non-invasive method could allow for early detection of treatment resistance, improving patient outcomes by enabling timely treatment adjustments, as prostate cancer rates continue to rise significantly.

ANGLE plc announced the issuance of 31,666 new ordinary shares following the exercise of employee options. The new shares, priced at £0.10 each, rank pari passu with existing shares, bringing the total to 234,973,717. An application for their admission to trading on AIM has been submitted, with trading set to begin at 8:00 a.m. on November 16, 2021. This move is part of ANGLE's ongoing efforts to enhance its liquid biopsy technology and maintain its competitive position in the healthcare market.

ANGLE plc (OTCQX:ANPCY) announced a change in its advisory team, appointing Berenberg as its Nominated Adviser and Joint Broker, and Jefferies as its Joint Broker, effective immediately. This strategic move aims to strengthen the company's market position as a leading liquid biopsy enterprise. ANGLE's proprietary Parsortix system, which targets circulating tumor cells for cancer analysis, is progressing towards FDA clearance for use with metastatic breast cancer patients and has shown promising results in clinical studies for ovarian cancer diagnostics.

ANGLE plc has announced the issuance of 15,666 new ordinary shares following employee option exercises. The New Ordinary Shares will rank equally with existing shares and are expected to be admitted for trading on AIM on October 27, 2021. This brings the total number of ordinary shares to 234,942,051, enhancing total voting rights.

ANGLE specializes in liquid biopsy technologies, particularly the Parsortix system, which captures circulating tumor cells for cancer analysis. The company continues to progress its clinical studies and patent portfolio.

ANGLE plc (OTCQX: ANPCY) announced the issuance of 30,000 new ordinary shares following the exercise of employee options. These shares will rank equally with existing shares and are expected to be admitted for trading on AIM on October 21, 2021. After this issuance, the total number of ordinary shares in circulation will be 234,926,385, impacting the total voting rights accordingly. ANGLE is recognized for its liquid biopsy technology, particularly the Parsortix system, which captures cancer cells for further analysis.

ANGLE plc (OTCQX: ANPCY), a leader in liquid biopsy technology, announced the issuance of 48,334 new ordinary shares following employee option exercises. These shares will rank equally with existing shares, bringing the total to 234,896,385 shares post-admission. The shares are expected to be traded on AIM starting October 6, 2021. This move does not directly reflect on revenue or market performance but indicates continued employee engagement and corporate governance.